PhotoSonix Medical is focused on addressing the challenges of moderate to severe acne, which affects over 20 million individuals in the U.S. The company highlights the limitations of current treatment options, noting that many patients do not respond to available therapies, and a significant portion of acne bacteria has developed antibiotic resistance. In response to this pressing issue, PhotoSonix Medical is developing CLENS™, an investigational device designed to provide a non-drug therapy for acne treatment. This innovative approach aims to offer an effective solution for the millions of patients seeking relief from the psychological and physical impacts of acne.

The CLENS™ device is currently under investigation and is not yet available for sale in the United States. PhotoSonix Medical holds several U.S. patents related to this technology, indicating a commitment to advancing their research and development efforts in the field of acne treatment. The company’s focus on non-drug therapies reflects a growing need for alternative solutions in dermatological care, particularly as traditional treatments face challenges such as resistance and limited efficacy.

United States

PhotoSonix Medical is developing a novel energy-based therapy called CLENS™ (Coincident Light Energy and Non-focused ultraSound).  CLENS synergistically combines light and ultrasound energy to treat human bacterial biofilms.  Initial focus is acne and dermal infections. 

Initial data is very exciting.  Currently raising capital.

PhotoSonix Medical

Company Details